Video

Dr. Botta on Unmet Needs in the Salvage Setting of GI Cancers

Gregory Botta, MD, PhD, discusses unmet needs in the salvage setting of gastrointestinal cancers.

Gregory Botta, MD, PhD, medical oncologist, associate professor of medicine, University of California, San Diego Health (UCSD), discusses unmet needs in the salvage setting of gastrointestinal cancers.

A phase 1b trial (NCT04404595) is evaluating CT041, a Claudin18.2 (CLDN18.2)–specific CAR T-cell therapy as another potential treatment option for patients with advanced gastric or pancreatic cancer.

Limited treatment options currently exist in the salvage setting for patients with advanced disease in these populations, Botta says. Additionally, comorbidities that increase over time make treatment decisions more difficult, Botta explains. For example, the patients may lose the ability to eat or drink, Botta adds.

By shifting treatments into earlier settings, patients may be able to benefit from these therapies before developed comorbidities become an issue, and that could prolong the time until patients need to be on chemotherapy, Botta concludes.

Related Videos
Jonathan Spicer, MD, PhD, FRCS
Daniel DeAngelo, MD, PhD
Marc J. Braunstein, MD, PhD, associate professor, Department of Medicine, co-director, Hematology-Oncology System, New York University (NYU) Grossman Long Island School of Medicine
Douglas W. Sborov, MD, MS, associate professor, Department of Internal Medicine—Division of Hematology and Hematologic Malignancies; director, Hematology Disease Center and Plasma Cell Dyscrasias Program, the University of Utah Huntsman Cancer Institute
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Binod Dhakal, MD
Sheldon M. Feldman, MD
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss ongoing research in gastrointestinal cancers.